[Autom. eng. transl.] The evidence that fixed combinations favor more persistent treatment than impromptu ones has led to focusing attention on these associations, which can also be a mandatory choice where monotherapy is no longer sufficient. Hence the development of the fixed combination of an angiotensin II receptor antagonist and a calcium channel blocker, which is the subject of this ethical evaluation in HTA (Health Technology Assessment).
|Translated title of the contribution||[Autom. eng. transl.] Ethical analysis in an HTA process of the fixed combination "olmesartan medoximil + amlodipine" in the treatment of high blood pressure|
|Number of pages||6|
|Journal||Italian Journal of Public Health|
|Publication status||Published - 2014|
- ipertensione arteriosa
- olmesartan medoximil+amlodipina